Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    STARTRK-2
Previous Study | Return to List | Next Study

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02568267
Recruitment Status : Recruiting
First Posted : October 5, 2015
Last Update Posted : June 8, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 2, 2024
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):